Zhixin Jiang

Mrs. Zhixin Jiang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MYMichael Youssef
Michael Youssef
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
ZJZhixin Jiang
Zhixin Jiang
DLDaniel Lim
Daniel Lim
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Cytology from cerebrospinal fluid (CSF) is standard-of-care to detect central nervous system (CNS) cancers but suffers from low-sensitivity and lacks associated molecular information, often requiring brain biopsy or resection to obtain. Belay Diagnostics offers analytically and clinically validated CSF-based tests to support the diagnosis and management of primary and secondary CNS cancers. However, the clinical utility (CU) of these assays has not been previously evaluated. Methods: This retrospective study presents a real-world, single institution experience of using the Belay Summit liquid biopsy test for all orders received (n = 123) between October 2024 and September 2025. Clinical information was reviewed for demographics, provisional diagnosis, oncology history, CSF cytology results, and tumor genomic profiling results. The primary endpoint of this study was to evaluate the impact of Belay CSF-based assays on physician diagnosis and treatment decisions. Secondary endpoints included evaluating the clinical performance of the Belay Summit test verses cytology in CNS malignancy detection (sensitivity, specificity, and accuracy). Results: The cohort included 120 patients with suspected or previously diagnosed primary (n = 40) or metastatic (n = 80) CNS tumors; three patients completed longitudinal testing for a total of 123 specimens and test orders. Summit showed higher sensitivity for CNS malignancy (90%) over CSF cytology (12%). The Belay CSF liquid biopsy test demonstrated strong clinical utility and was essential to clinical course pursued in 93% (114/123) of specimens, informing treatment and management decisions. Conclusions: The Belay Summit test provides clinically meaningful information to support physician decision-making for the diagnosis and management of primary and secondary CNS tumors, especially in cases where tissue sampling is infeasible.

1 August 2019 in Patient Education and Counseling
Verified
Journal Article
Closed access
JFJennifer Freytag
Jennifer Freytag
ZJZhixin Jiang
Zhixin Jiang
TGThomas Peter Giordano
Thomas Peter Giordano
RWRobert A. Westbrook
Robert A. Westbrook
SMSheryl McCurdy
Sheryl McCurdy
BDBich N. Dang
Bich N. Dang

12 May 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
ZJZhixin Jiang
Zhixin Jiang
CCChunyu Cai
Chunyu Cai
NSNawal Shaikh
Nawal Shaikh
WHWilliam Hyman
William Hyman
Extraneural metastasis of glioblastoma (GBM) is rare but expected to increase in incidence as patients live longer. We present a rare case of GBM that has metastasised to the bone marrow shortly after completing standard of care treatment. This case highlights the importance of having a high index of suspicion, using next-generation sequencing testing and the urgent need for further research to identify treatment options for this population.